AGP Executive Report
Last update: 9 hours agoMedical Cannabis R&D: Exilby (VER-01), a cannabis-derived, non-opioid oral pain therapy, is advancing through regulatory review in Europe and the U.S., with Germany/Austria already approving it for chronic low back pain and the FDA granting Breakthrough Therapy status ahead of a pivotal Phase 3 readout target in 2027. Public Safety & Illicit Drug Risk: UK reports warn of cannabis being sprayed with synthetic opioids like nitazenes, with experts citing scary non-fatal overdoses among people who don’t use opiates. Youth & Health Trends: Vermont’s survey data suggests teen mental health is improving and vaping/drinking/cannabis use is down, though poor mental health still affects about one in four high school students. Enforcement & Trade: Hong Kong Customs seized about 32kg of suspected cannabis buds worth ~$7.5M at the airport, arresting a British transit passenger. Industry Compliance & Market Integrity: Colorado coverage highlights “THC inflation” concerns, where lab tests found products often miss labeled THC and fail safety limits. Policy & Access: Colorado Gov. Jared Polis issued additional pardons for past marijuana convictions, adding to thousands of cannabis clemency acts.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
